• Publications
  • Influence
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.
TLDR
Reaction phenotyping of NVP to its four oxidative metabolites indicates that NVP is principally metabolized by CYP3A4 and CYP2B6 and that it has little potential to be involved in inhibitory drug interactions. Expand
Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)
TLDR
The current (EILAT IX) manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development, including brivaracetam, carisbamate, eslicarbazepine acetate and YKP-3089. Expand
Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.
TLDR
The findings indicate that CYP3A4 is the principal catalyst of 10,11-epoxide formation in human liver, consistent with the number of inhibitory drug interactions associated with its clinical use, interactions that result from a perturbation of CYP 3A4 catalytic activity. Expand
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
TLDR
This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate, fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369. Expand
Metabolic Drug Interactions
TLDR
The progress on metabolic drug interactions is reviewed in order to cause the attention of medical staff and take measures to cut down the frequency of ADRs caused by unreasonable metabolicDrug interactions. Expand
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
TLDR
This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel,ucb 34714 and valrocemide, as well as updates on second-generation AEDs. Expand
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
TLDR
Information presented on drugs in preclinical and clinical development, including carabersat, CGX-1007 (Conantokin-G), pregabalin, retigabine (D-23129), safinamide, SPD421 (DP-VPA), SPM 927, talampanel and valrocemide are summarized. Expand
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
TLDR
A review of drugs in development and recently marketed AEDs and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available. Expand
New Antiepileptic Drugs: Review on Drug Interactions
TLDR
These newer antiepileptic drugs exhibit a lower potential for drug interactions than the classic AEDs, like phenytoin, carbamazepine and valproic acid, mostly because of their pharmacokinetic characteristics. Expand
Cytochrome P450 Isozymes and Antiepileptic Drug Interactions
  • R. Levy
  • Chemistry, Medicine
  • Epilepsia
  • 1 May 1995
Summary: Recent findings about individual isoforms of the cytochromes P450 involved in the metabolism of phe‐nytoin (PHT) and carbamazepine (CBZ) make prediction of inhibition‐based interactionsExpand
...
1
2
3
4
5
...